{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:40:23Z","timestamp":1756287623588,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1136\/dtb.2019.000085","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T17:15:27Z","timestamp":1579194927000},"page":"39-40","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose PPI and aspirin as chemoprevention in Barrett\u2019s oesophagus"],"prefix":"10.1136","volume":"58","author":[{"given":"Kuku","family":"Moyo","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, St George\"s University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teck K","family":"Khong","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, St George\"s University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"2025082702065348000_58.3.39.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31388-6"},{"key":"2025082702065348000_58.3.39.2","unstructured":"Cancer Reseasrch UK . Oesophageal cancer survival statistics [online]. 2019. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/oesophageal-cancer\/survival#heading-Zero [Accessed 20 November 2019]."},{"key":"2025082702065348000_58.3.39.3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025082702065348000_58.3.39.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305997"},{"key":"2025082702065348000_58.3.39.5","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50008"},{"key":"2025082702065348000_58.3.39.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305372"},{"key":"2025082702065348000_58.3.39.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1805819"},{"key":"2025082702065348000_58.3.39.8","doi-asserted-by":"crossref","unstructured":"Xie Y , Bowe B , Yan Y , et al . Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365.doi:10.1136\/bmj.l1580","DOI":"10.1136\/bmj.l1580"},{"key":"2025082702065348000_58.3.39.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803955"},{"key":"2025082702065348000_58.3.39.10","unstructured":"Summary of Product Characteristics . Nexium 40 Mg tablets. UK: AstraZeneca UK Limited, 2019."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2019.000085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:07:06Z","timestamp":1756285626000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2019.000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/dtb.2019.000085"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2019.000085","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}